BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26687013)

  • 1. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
    Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
    Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load.
    Calabrese F; Loy M; Lunardi F; Marino D; Aversa SM; Rea F
    Transpl Infect Dis; 2010 Aug; 12(4):342-6. PubMed ID: 20030794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
    Solano C; Mateo EM; Pérez A; Talaya A; Terol MJ; Albert E; Giménez E; Vinuesa V; Piñana JL; Boluda JCH; Navarro D
    J Clin Virol; 2017 Dec; 97():26-32. PubMed ID: 29096390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
    Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
    Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
    J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
    Papalexandri A; Gavriilaki E; Vardi A; Kotsiou N; Demosthenous C; Constantinou N; Touloumenidou T; Zerva P; Kika F; Iskas M; Batsis I; Mallouri D; Yannaki E; Anagnostopoulos A; Sakellari I
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
    Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH
    J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.